IP Library Granted Patent US 10,133,089
Granted Patent B2
US 10,133,089 · App. 15/139,513 · Granted Nov 20, 2018

Cast molding toric contact lenses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,133,089
App. No.
15/139,513
Granted
Nov 20, 2018
Kind
B2
Abstract

A system and a method of cast molding toric contact lenses permits aligning first and second mold sections at multiple rotational positions. Each mold section includes a set of alignment features that engage with complementary alignment features on the other mold section.

Claims (26)

1. A contact lens mold assembly comprising:

(a) a first contact lens mold section and a second contact lens mold section which are alignable at multiple rotational positions with respect to one another and each of which includes a molding surface;

(b) the molding surface of one of the first and second mold sections shaped to provide a molded contact lens with a stabilization feature, and the molding surface of the other of the first and second mold sections shaped to provide a molded contact lens with an optical zone having a cylindrical optical correction;

(c) the molding surface of one of the first and second mold sections including an anterior contact lens-molding surface, and the molding surface of the other of the first and second mold sections including a posterior contact lens-molding surface;

(d) the first mold section includes a first set of rotational alignment features disposed angularly symmetrically on a circumference surrounding the first mold section lens-molding surface, and the second mold section includes a second set of rotational alignment features disposed angularly asymmetrically on a circumference surrounding the second mold section lens-molding surface.

2. The mold assembly of claim 1 , wherein for a specific rotational position of the first and second mold sections, a first rotational alignment feature in the first set contacts physically a first rotational alignment feature of the second set to prevent clockwise rotation of the first mold section, and a second, different rotational alignment feature in the first set contacts physically a second, different rotational alignment feature of the second set to prevent counterclockwise rotation of the first mold section.

3. The mold assembly of claim 1 , wherein for a specific rotational position of the first and second mold sections, a first rotational alignment feature in the first set contacts physically a first rotational alignment feature of the second set to prevent only clockwise rotation of the first mold section, and a second, different rotational alignment feature in the first set contacts physically a second, different rotational alignment feature of the second set to prevent only counterclockwise rotation of the first mold section.

4. The mold assembly of claim 1 , wherein the rotational alignment features of the first and second sets are molded into the contact lens mold sections when the contact lens mold sections are formed by injection molding.

5. The mold assembly of claim 1 , wherein each rotational alignment feature in the first set is arranged to contact more than one rotational alignment feature of the second set, depending on a specific rotational position.

6. The mold assembly of claim 1 , wherein the rotational positions of the first and second mold sections are evenly spaced angularly such that Δi° represents an equal angular spacing between adjacent rotational positions, and a number (n1) of rotational alignment features in the first set and a number (n2) of rotational alignment features in the second set is defined by n1×n2×Δi°=360°, and wherein each of n1 and n2 is at least three.

7. The mold assembly of claim 6 , wherein Δi° represents 10°, and n1×n2=36.

8. The mold assembly of claim 7 , where n1 and n2 each is six.

9. The mold assembly of claim 1 , wherein the first set of rotational alignment features are protrusions extending from an annular surface surrounding the first mold section lens-molding surface, said protrusions spaced evenly around the annular surface.

10. The mold assembly of claim 9 , wherein the second set of rotational alignment features are protrusions extending from an annular surface surrounding the second mold section lens-molding surface, said protrusions spaced unevenly around the annular surface.

11. A method of cast molding a contact lens, comprising:

(a) providing a first contact lens mold section and a second contact lens mold section, wherein a lens-molding surface of one of the first and second mold sections is shaped to provide a molded contact lens with a stabilization feature and a lens-molding surface of the other of the first and second mold sections is shaped to provide a molded contact lens with an optical zone having a cylindrical optical correction, and wherein the lens-molding surface of one of the first and second mold sections includes an anterior contact lens-molding surface and the lens-molding surface of the other of the first and second mold sections includes a posterior contact lens-molding surface;

(b) the first mold section including a first set of rotational alignment features thereon and disposed angularly symmetrically on a circumference surrounding the first mold section lens-molding surface, and the second mold section including a second set of rotational alignment features thereon and disposed angularly asymmetrically on a circumference surrounding the second mold section lens-molding surface, such that the first and second mold sections are alignable at multiple rotational positions;

(c) engaging the first and second mold sections with respect to one another at a specific rotational position, such that a first rotational alignment feature in the first set contacts physically one of the rotational alignment features of the second set to prevent clockwise rotation of the first mold section, and a second, different rotational alignment feature in the first set contacts physically a different alignment feature of the second set to prevent counterclockwise rotation of the first mold section; and

(d) curing a polymerizable lens-forming mixture in a lens-shaped molding cavity formed between the anterior and posterior contact lens-molding surfaces.

12. The method of claim 11 , wherein contact between said first rotational alignment feature in the first set and said one of the rotational alignment features of the second set prevents only clockwise rotation of the first mold section, and contact between said second rotational alignment feature in the first set and said second, different rotational alignment feature of the second set prevents only counterclockwise rotation of the first mold section.

13. The method of claim 11 , wherein the rotational alignment features of the first and second sets are molded into the contact lens mold sections when the contact lens mold sections are formed by injection molding.

14. The method of claim 11 , wherein each rotational alignment feature in the first set is arranged to contact more than one rotational alignment feature of the second set, depending on a specific rotational position.

15. The method of claim 11 , wherein specific rotational positions of the first and second mold sections are evenly spaced angularly such that Δi° represents an equal angular spacing between adjacent rotational positions, and a number (n1) of rotational alignment features in the first set and a number (n2) of rotational alignment features in the second set is defined by n1×n2×Δi°=360°, and wherein each of n1 and n2 is at least three.

16. The method of claim 15 , wherein Δi° represents 10°, and n1×n2=36.

17. The method of claim 11 , wherein the first set of rotational alignment features are protrusions extending from an annular surface surrounding the first mold section lens-molding surface, said protrusions spaced evenly around the annular surface.

18. The method of claim 11 , wherein the second set of rotational alignment features are protrusions extending from an annular surface surrounding the second mold section lens-molding surface, said protrusions spaced unevenly around the annular surface.

Assignments (22)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061872/0099 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 042584/0861) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061775/0655 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
SECURITY AGREEMENT Recorded May 25, 2017
From: ALDEN OPTICAL LABORATORIES, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SPROUT PHARMACEUTICALS, INC.; SYNERGETICS USA, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 042584/0861 →